Enhanc3D Genomics, a Cambridge, UK-based a functional genomics company, raised £10M in Series A funding.
The round was led by BGF, and Parkwalk Advisors, with participation from Bioqube Ventures.
The company intends to use the funds to accelerate the development of its proprietary technology platform “GenLink3D“, also expand its team.
Led by CEO Debora Lucarelli, Enhanc3D is a functional data science biotech company whose platform, GenLink3D, aims to unlock the potential of the three-dimensional organisation of DNA. Enhanc3D’s proprietary technology directly measures DNA interactions controlling gene regulation, allowing the exploration of the uncharted non-coding regions of the DNA, which account for about 98% of the entire genome. Initially, the platform will generate large datasets across multiple immune-cell types that have broad relevance to auto-immune diseases, cancer and ageing.
FinSMEs
20/10/2022